Oorsprong van het eerstegraads netwerk van Zhen Yao
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Public Company | Medical/Nursing Services | 3 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Zhen Yao via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
University of Oxford | College/University | Doctorate Degree | |
Zhejiang University | College/University | Doctorate Degree | |
Roche (China) Co. Ltd. | Chief Tech/Sci/R&D Officer | ||
COLAND HOLDINGS LIMITED | Pharmaceuticals: Major | Director/Board Member | |
Shanghai Guo Chuang Pharmaceutical Co., Ltd.
Shanghai Guo Chuang Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Guo Chuang Pharmaceutical Co., Ltd. principally engages in the research, development, production, and sale of pharmaceutical products. Its products include pharmaceuticals against nervous system diseases, digestive system diseases, cardiovascular diseases, mental diseases, and immune system diseases. The company was founded on March 20, 2003 and is headquartered in Shanghai, China. | Pharmaceuticals: Major | Director/Board Member | |
HANGZHOU TIGERMED CONSULTING CO., LTD | Miscellaneous Commercial Services | Chairman | |
Shanghai LIDE Biotech Co. Ltd.
Shanghai LIDE Biotech Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai LIDE Biotech Co. Ltd. is a translational medicine service provider that specializes in oncology translational research and immuno oncology. The private company is based in Shanghai, China. The Chinese company has a growing bank of over 50 cell line-derived xenograft (cdx) mouse models that are used for preclinical drug efficacy testing. The benefits of cdx models are their cost effectiveness, fast turnaround time, and high efficiency of xenotransplantation. LIDE's FGI (Functional Genomic Imaging) platform leverages its K-cell technology and bioinformatics team to deliver next-generation transcription analysis. The primary benefit of CR (Conditionally Reprogrammed) cells is their intratumor and intertumor heterogeneity, even after amplification. | Miscellaneous Commercial Services | Director/Board Member | |
HBM HOLDINGS LIMITED | Pharmaceuticals: Other | Director/Board Member | |
Macquarie Business School | College/University | Masters Business Admin |
Statistieken
Internationaal
China | 8 |
Verenigd Koninkrijk | 2 |
Kaaimaneilanden | 2 |
Australië | 2 |
Sectoraal
Consumer Services | 4 |
Health Technology | 4 |
Commercial Services | 3 |
Health Services | 2 |
Operationeel
Director/Board Member | 6 |
Doctorate Degree | 2 |
Director of Finance/CFO | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Chief Executive Officer | 1 |
Sterkste connecties
Insiders | |
---|---|
Xiao Ping Ye | 9 |
De Kang Zhao | 3 |
Yu Peng Shi | 1 |